Gene editing has the potential to eliminate genetic diseases, make crops more nutritious, and target viruses like HIV, but at what cost? In 2018, a Chinese scientist sparked international outrage after claiming he used CRISPR to make the first-ever gene-edited babies. It’s a tremendous leap for biotechnology, but how can this technology be used responsibly? What are the implications of designing our world on a molecular level? A conversation about how-and if-our ethics, laws, and boundaries can keep pace with CRISPR.
Dr. Udit Batra, Chief Executive Officer, MilliporeSigma; Executive Board Member; Merck KGaA, Darmstadt, Germany
Paul Dabrowski, Chief Executive Officer, Synthego
Dr. Rachel Haurwitz, President and CEO, Caribou Biosciences
Moderator: Sy Mukherjee, FORTUNE
Subscribe to Fortune -
kzfaq.info_c...
FORTUNE is a global leader in business journalism with a worldwide circulation of more than 1 million and a readership of nearly 5 million, with major franchises including the FORTUNE 500 and the FORTUNE 100 Best Companies to Work For. FORTUNE Live Media extends the brand's mission into live settings, hosting a wide range of annual conferences, including the FORTUNE Global Forum.
Website: fortune.com/
Facebook: / fortunemagazine
Twitter: / fortunemagazine